Fulgent Genetics Expects 2024 Core Revenue of Approximately $280M Versus Consensus Of $294.25M, With Adjusted EPS Loss Of Approximately $(1.05) Versus Consensus Of $(0.95)
Portfolio Pulse from Benzinga Newsdesk
Fulgent Genetics (FLGT) projects its 2024 core revenue to be around $280M, falling short of the consensus estimate of $294.25M. Additionally, it anticipates an adjusted EPS loss of approximately $(1.05), which is worse than the consensus forecast of $(0.95).
February 28, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fulgent Genetics projects lower-than-expected 2024 core revenue and a greater adjusted EPS loss than consensus estimates.
Fulgent Genetics' projection of lower-than-expected revenue and a greater loss per share for 2024 could lead to negative investor sentiment in the short term. This news directly impacts the company's financial outlook, making it highly relevant and important for investors. The confidence in this analysis is high due to the clear discrepancy between the company's projections and consensus estimates.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100